Amylyx Pharmaceuticals (AMLX) Winds Up Avexitide Phase 3 Lucidity Trial Enrollment [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
On March 24, Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) stated that the final subject in the Phase 3 Lucidity clinical study of avexitide had been randomised and dosed. This 16-week multicentred, randomised, double-blind, placebo-controlled study examines the safety and effectiveness of avexitide in adults with PBH following Roux-en-Y gastric bypass surgery. Patricia Chumillas/Shutterstock.com If participants finish the 16-week double-blind phase, the trial can be extended for an additional 32 weeks. 78 people have signed up for the trial, and the topline data readout is scheduled for the third quarter of 2026. Avexitide is expected to go on sale in 2027 if approved. On March 4, H.C. Wainwright analyst Andrew Fein increased the firm's price target on Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) from $28 to $34. The firm maintained its Buy rating on the shares. The move follows recent engagement with investors and experts, who expressed strong enthusiasm for the Phase 3 LUCIDITY t
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch [Yahoo! Finance]Yahoo! Finance
- Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR Newswire
- Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Is LUCIDITY Trial Completion in Post-Bariatric Hypoglycemia Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $34.00 price target on the stock.MarketBeat
AMLX
Earnings
- 3/3/26 - In-Line
AMLX
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/24/26 - Form 8-K
- 3/9/26 - Form 4
- AMLX's page on the SEC website